Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Sham-controlled, Double-masked, Multicenter Study Evaluating Ocriplasmin Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole

NCT01429441 is registered in ClinicalTrials.gov with ThromboGenics as lead sponsor.

NCT NCT01429441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01429441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Sham-controlled, Double-masked, Multicenter Study Evaluating Ocriplasmin Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole
Lead sponsor
ThromboGenics
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2011
Completion date
October 31, 2014
Enrollment
220 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

vitreomacular adhesion including macular hole